ANI Pharmaceuticals (NASDAQ: ANIP) exec sells 5,323 shares in 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Christopher Mutz reported an open-market sale of company stock. On the reported date, he sold 5,323 shares of ANI Pharmaceuticals common stock at a weighted average price of $78.02 per share, with individual trade prices ranging from $77.20 to $78.58.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After this sale, Mutz directly holds 84,840 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 5,323 shares ($415,300)

Net Sell 1 txn

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Sold 5,323 shs ($415K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,323	$78.02	$415K

Holdings After Transaction: Common Stock — 84,840 shares (Direct)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $77.20 to $78.58. The price reported above reflects the weighted average sales price.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/23/2026 - 05:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last)

(First)

(Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE

56623

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2026		S⁽¹⁾		5,323	D	$78.02⁽²⁾	84,840	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. The shares were sold in multiple trades at prices ranging from $77.20 to $78.58. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ANIP executive Christopher Mutz report?

Christopher Mutz reported selling 5,323 shares of ANI Pharmaceuticals common stock. The shares were sold in an open-market transaction at a weighted average price of $78.02 per share, reflecting multiple individual trades within a disclosed price range.

At what prices did Christopher Mutz sell ANIP shares in this Form 4?

The reported ANIP shares were sold at prices ranging from $77.20 to $78.58 per share. The Form 4 lists a weighted average sale price of $78.02 per share, summarizing multiple individual trades executed within that range.

How many ANIP shares does Christopher Mutz own after this reported sale?

After the reported transaction, Christopher Mutz directly owns 84,840 shares of ANI Pharmaceuticals common stock. This figure reflects his remaining direct holdings following the sale of 5,323 shares disclosed in the Form 4 filing.

Was the ANIP insider sale by Christopher Mutz under a 10b5-1 trading plan?

Yes, the sale was conducted under a Rule 10b5-1 trading plan. The footnotes state the plan was adopted by Christopher Mutz on June 16, 2025, providing a pre-arranged framework for executing these stock sales over time.

What role does insider Christopher Mutz hold at ANI Pharmaceuticals (ANIP)?

Christopher Mutz is identified as an officer of ANI Pharmaceuticals, serving as Head of Rare Disease. His position is disclosed in the Form 4, which reports his direct ownership and the recent open-market sale of company common stock.